Outlook’s wet AMD treatment accepted by SMC for NHS Scotland
The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava to treat wet age-related macular degeneration (wet AMD).
The Scottish Medicines Consortium (SMC) has accepted Outlook Therapeutics’ Lytenava to treat wet age-related macular degeneration (wet AMD).
What's Your Reaction?
